AIA Group Ltd Has $1.98 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

AIA Group Ltd grew its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 192.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 47,640 shares of the company's stock after purchasing an additional 31,349 shares during the period. AIA Group Ltd's holdings in Moderna were worth $1,981,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB lifted its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna in the fourth quarter valued at about $37,000. Venturi Wealth Management LLC boosted its position in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares during the period. Crowley Wealth Management Inc. bought a new position in shares of Moderna during the fourth quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after buying an additional 389 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Up 2.1 %

NASDAQ MRNA traded up $0.56 on Wednesday, hitting $27.72. 11,792,223 shares of the company's stock were exchanged, compared to its average volume of 6,943,608. Moderna, Inc. has a 52 week low of $26.32 and a 52 week high of $170.47. The stock has a 50-day moving average of $34.43 and a 200-day moving average of $43.55. The stock has a market cap of $10.72 billion, a price-to-earnings ratio of -2.99 and a beta of 1.86.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MRNA. Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Citigroup initiated coverage on shares of Moderna in a research note on Thursday, March 13th. They set a "neutral" rating and a $40.00 price objective for the company. Morgan Stanley lowered their target price on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Wednesday, January 15th. Finally, Bank of America reduced their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Moderna presently has an average rating of "Hold" and an average price target of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.